Ozomet-VG 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control without causing significant hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, mitigating postprandial hyperglycemia. The combined action of these agents targets multiple pathophysiological defects in type 2 diabetes, offering improved glycemic regulation. Ozomet-VG 2 Tablet PR is indicated for patients inadequately controlled on diet, exercise, and monotherapy or dual therapy with these agents. It should be administered under medical supervision, with dosage adjustments based on glycemic response and tolerance. Caution is advised in patients with renal or hepatic impairment, and monitoring for potential adverse effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis is essential. This combination therapy supports comprehensive diabetes management, aiming to reduce the risk of microvascular and macrovascular complications.